Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-17 | Mr. Bradbury is the founder and Managing Member of BioBrit, LLC, a life sciences consulting firm and investment fund. He has a Bachelor of Pharmacy and a Diploma in Management Studies. |
| 2014-04-07 | Mr. Bradbury has been CEO of Amylin Pharmaceuticals and serves on boards of life sciences companies; educational background in Pharmacy and Management Studies. |
| 2015-04-20 | He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. Our Board selected Mr. Bradbury to serve as a director because he brings to our Board extensive experience in operations and management in the pharmaceutical industry. |
| 2016-04-22 | Mr. Bradbury is founder and Managing Member of BioBrit, LLC, and has held executive roles in pharmaceutical companies. He holds a Bachelor of Pharmacy and a Diploma in Management Studies. |
| 2017-04-21 | Daniel M. Bradbury has served as a member of our Board since October 2012. Mr. Bradbury is the founder and Managing Member of BioBrit, LLC, a life sciences consulting firm and investment fund. Mr. Bradbury served as President and Chief Executive Officer of Amylin from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| 2018-04-24 | Daniel M. Bradbury has served as a member of our Board since October 2012. Mr. Bradbury is the Founder and Managing Member of BioBrit, LLC, a life sciences consulting and investment firm and Chief Executive Officer, Chairman and Co-Founder of Equillium, Inc., a private biopharmaceutical company focused on developing first-in-class therapies to treat severe autoimmune disorders with high unmet medical need. Mr. Bradbury served as President and Chief Executive Officer of Amylin from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. |
| Filing Date | Source Excerpt |
|---|---|
| 2013-04-05 | Daniel M. Bradbury has served as a director of Geron since September 2012. ... Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc. ... The Board believes that Mr. Bradbury's extensive experience in the biopharmaceutical industry ... qualifies Mr. Bradbury to be nominated as a director. ... The Audit Committee, which is comprised of Ms. Eastham and Messrs. Bradbury (who joined in September 2012), Fritzky and Kiley, met seven times in 2012. ... The following table provides compensation information for the fiscal year ended December 31, 2012 for each non-employee member of the Board. ... Bradbury, Daniel $14,503 in fees and $76,244 in option awards totaling $90,747. |
| 2014-04-04 | Daniel M. Bradbury has served as a director of Geron since September 2012. He also serves as a member of the boards of directors of Illumina, Inc., a manufacturer of life-science tools and integrated systems for the analysis of genetic variation and biological function; Corcept Therapeutics, a company focused on the discovery and development of drugs that regulate the effects of cortisol; BioCon Ltd., a company focused on reducing therapy costs of chronic diseases like diabetes, cancer and autoimmune diseases; and BioMed Realty, a real estate investment trust focused on providing real estate to the life science industry, as well as being a member of the board of trustees of the Keck Graduate Institute. He also serves on the University of California San Diego, Rady School of Management's Advisory Council, the University of Miami's Innovation Corporate Advisory Council, Investor Growth Capital Advisory Board and the BioMed Ventures Advisory Committee. Mr. Bradbury served as Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company focused on diabetes and metabolic disorders, from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Mr. Bradbury served as Amylin's President from June 2006 until March 2007, as Chief Operating Officer from June 2003 until June 2006, as Executive Vice President from June 2000 until June 2003 and in other positions in corporate development and marketing from 1994 until 2000. In addition, Mr. Bradbury served as a member of the board of directors of Amylin from June 2006 until August 2012. Prior to joining Amylin, he spent ten years at SmithKline Beecham Pharmaceuticals, a pharmaceutical company, holding a number of sales and marketing positions. He received a Bachelor of Pharmacy from Nottingham University and a Diploma in Management Studies from Harrow and Ealing Colleges of Higher Education in the United Kingdom. The Board believes that Mr. Bradbury's extensive experience in the biopharmaceutical industry, together with his experience in the research, development and commercialization of pharmaceutical drug products, qualifies Mr. Bradbury to serve as a director. |
| 2015-04-03 | Daniel M. Bradbury has served as a director since September 2012. He is a member of the Audit Committee. Compensation Table shows total compensation of $103,950. |
| 2016-04-01 | Daniel M. Bradbury has served as a director of Geron since September 2012. ... The Audit Committee, which is comprised of Ms. Eastham, Mr. Bradbury and Dr. Lawlis, met nine times in 2015. ... The Nominating and Corporate Governance Committee will consider nominees for director nominated by stockholders upon submission in writing to our Corporate Secretary of the names of such nominees in accordance with our Bylaws. ... The following table provides compensation information for the fiscal year ended December 31, 2015 ("fiscal 2015"), for each non-employee member of the Board who served in such capacity during fiscal 2015. ... Bradbury, Daniel $ 58,091 $ 96,229 $ 154,320 |
| 2017-03-24 | Daniel M. Bradbury 55 Yes M, FE M 3 Independent Director ... Geron Committee Memberships - Audit Committee - Nominating and Corporate Governance Committee ... Director Compensation Table ... Bradbury, Daniel $60,000 $97,760 $157,760 |
| 2018-03-30 | Daniel M. Bradbury 56 Yes M, FE M 2 Independent Director |
| 2019-04-22 | Daniel M. Bradbury 57 Yes M FE M 3 Independent Director In connection with his decision not to stand for re-election due to his new responsibilities as a chief executive officer for another public company, Mr. Bradbury will not be standing for re-election at the Annual Meeting; accordingly, his term of office will expire at the Annual Meeting. |
Data sourced from SEC filings. Last updated: 2026-02-03